BIOCLINICA, INC. TO PARTICIPATE IN UPCOMING INDUSTRY EVENTS AND DEMONSTRATE GLOBAL TECHNOLOGY-ENHANCED CAPABILITIES

NEWTOWN, PA, April 18, 2012 – BioClinica®, Inc. (NASDAQ: BIOC), a global provider of clinical trial management solutions, today announced that members of its team will attend, participate in and speak at several upcoming industry conferences in April, May, and June. BioClinica experts will discuss industry trends and also demonstrate the company’s suite of technologies and solutions. The conferences include:

64th Annual American Academy of Neurology Meeting
April 21 – 28, 2012
New Orleans, Louisiana
Booth #747

The American Academy of Neurology Annual Meeting is the biggest neurology event in the world and promises to be a valuable experience with a customizable schedule of education, science, and practice programs. Dr. Chahin Pachai will demonstrate BioClinica’s technology-enhanced imaging core lab expertise and trial management services at the AAN Meeting. Dr. Pachai is the Vice President and Executive Director of BioClinica’s Lyon, France office and is an expert in the field of quantitative MRI, image segmentation and CNS diseases.

Global Clinical Supplies Group
April 22 – 25, 2012
Irvine, California
Booth #21

Global Clinical Supplies Group is a forum for open discussion to share knowledge and the industry's best practices for clinical supply and related professionals. The GCSG conference is the most comprehensive conference in the clinical supply chain arena. BioClinica will demonstrate its suite of clinical trial services that maximize efficiency and manageability of the clinical trial process.

DIA Clinical Data Quality Summit
April 24 – 25, 2012
Philadelphia, Pennsylvania

The Drug Information Association’s Clinical Data Quality Summit features a mix of highly interactive plenary and breakout sessions. Participants will troubleshoot, share processes, and exchange ideas with colleagues from various clinical areas while exploring new tools, technologies, and techniques for conducting remote-based and targeted monitoring. Jonathan Andrus, BioClinica’s Senior Vice President of Operations, is a member of the program committee and will chair the Study Conduct session with Dr. Sean Kassim of the FDA.

-more-
2012 OARSI World Congress on Osteoarthritis  
April 26 – 29, 2012  
Barcelona, Spain

The annual Osteoarthritis Research Society International (OARSI) Congress is a global forum for all people involved in osteoarthritis research and treatment. This meeting features speakers from around the world presenting up-to-date information on a wide range of topics related to joint damage and osteoarthritis. Dr. Colin G. Miller, BioClinica’s Senior Vice President of Medical Affairs, will be co-authoring an oral presentation given by Dr. Marie-Pierre Hellio Le Graverand of Pfizer Global Research and Development. The presentation is entitled “A 2-year randomized, double-blind, placebo-controlled, multicenter study of oral selective iNOS inhibitor, cindunistat, in patients with symptomatic osteoarthritis of the knee”.

Outsourcing in Clinical Trials Europe  
May 8 – 9, 2012  
Zurich, Switzerland  
Booth #24

The growing complexity and global nature of modern clinical trials makes the need to outsource greater than ever. Outsourcing in Clinical Trials bring major pharmaceutical and biotech manufacturers together to debate potential solutions to the complex challenges of running global clinical trials. BioClinica representatives will attend the conference to demonstrate the company’s industry-leading eClinical solutions and Imaging Core Lab services.

Outsourcing in Clinical Trials Southeast  
May 15 – 16, 2012  
Durham, North Carolina  
Booth #22

The growing complexity and global nature of modern clinical trials makes the need to outsource greater than ever. The Outsourcing in Clinical Trials Southeast conference promises to provide an exclusive hub for stimulating innovative thought and adaptable proactive solutions. The event will tackle major concerns of outsourcing such as vendor selection and management, patient recruitment in the emerging markets, data management, FDA regulations and many more challenges. BioClinica representatives will attend the conference to demonstrate the company’s industry-leading eClinical solutions and Imaging Core Lab services.

American Society of Clinical Oncology Annual Meeting  
June 1 – 5, 2012  
Chicago, Illinois  
Booth # 16105

Bringing together more than 30,000 oncology professionals from a broad range of specialties, the 2012 ASCO Annual Meeting will feature cutting-edge scientific presentations and comprehensive educational content. More than 5,000 abstracts are accepted each year, showcasing the latest breakthroughs in the progress against cancer with important and sometimes immediate implications for patient care and practice. Dr. Andy Dzik-Jurasz, BioClinica’s Senior Medical Director, will be in attendance. Dr. Dzik-Jurasz has over 15 years of experience in oncology radiology. In addition, Mirada Medical and BioClinica will jointly demonstrate the expanded molecular imaging capabilities that BioClinica can provide through their recently announced partnership.
Clinical Trial Oversight Summit
June 4 – 7, 2012
Boston, Massachusetts

The inaugural Clinical Trial Oversight Summit will include presentations from experts, case studies, interactive breakout discussion groups, workshops, and networking opportunities. Topics will include risk-based approaches to clinical trial management, implementing quality systems-based approaches to GCP compliance, ensuring reliable study data, responding to the evolving regulatory landscape, and preparing sites and clinical research partners for inspection-readiness. Jonathan Andrus, BioClinica’s Senior Vice President of Operations, will present the topic “Partnering for Clinical Trial Success: Johnson and Johnson Vision Care (Vistakon) and BioClinica.”

Annual EULAR 2012 Congress
June 6 – 9, 2012
Berlin, Germany

The aim of the European League Against Rheumatism (EULAR) annual congress is to provide a forum of the highest standard for scientific, educational, and social exchange between professionals involved in rheumatology, liaising with patient organizations, in order to achieve progress in the clinical care of patients with rheumatic diseases. BioClinica Medical Affairs staff members Dr. Colin G Miller and Dr. Harris Ahmad will be in attendance and will co-author two poster presentations with Prof. Desiree van der Heijde of Leiden University Medical Center titled "Calculation of the Smallest Detectable Change (SCD) of Radiographic Progression in Clinical Trials with Multiple Time Points: The Mean SDC is a Valid Approximation of the Overall SDC and Prediction of Rate of Adjudication of Radiological Progression in Rheumatoid Arthritis (RA) Randomized Controlled Trials (RCTs) in Early and Established Disease."

Drug Information Association 48th Annual Meeting
June 24 – 28, 2012
Philadelphia, PA
Booth #2707

The DIA annual meeting is the pharmaceutical industry’s premier event. More than 7,500 professionals involved in the discovery, development, and life cycle management of pharmaceuticals, biotechnology, medical devices, and related products will come together to foster innovation and facilitate health and well-being worldwide. BioClinica will demonstrate its innovative eClinical solutions and leading Imaging Core Lab services. Jonathan Andrus, BioClinica’s Senior Vice President of Operations and chair of the DIA eClinical SIAC showcase session, will speak on June 26th in the 3:30pm session on “Controversial Guidance, eSource and Standards: How Does It All Fit Together in an eClinical World?”

About BioClinica, Inc.
BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management solutions. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, clinical trial management and clinical supply chain design and optimization solutions. BioClinica solutions maximize efficiency and manageability throughout all phases of the clinical trial process. With over 20 years of experience and more than 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com.

Certain matters discussed in this press release are “forward-looking statements” intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company’s financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or...
cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances. You should review the Company’s filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.

########